RxSight, Inc. (RXST)

Market Cap	334.05M
Revenue (ttm)	41.34M
Net Income (ttm)	-66.88M
Shares Out	27.67M
EPS (ttm)	-3.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,447
Open	11.99
Previous Close	12.05
Day's Range	11.55 - 12.28
52-Week Range	8.8 - 16.99
Beta	n/a
Analysts	Buy
Price Target	20.66 (+71.9%)
Earnings Date	Nov 7, 2022

About RXST

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction ...

• Industry: Medical Devices
• IPO Date: Jul 30, 2021
• Employees: 221
• Stock Exchange: NASDAQ
• Ticker Symbol: RXST

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RXST stock is "Buy." The 12-month stock price forecast is 20.66, which is an increase of 71.88% from the latest price.

Price Target

$20.66

(71.88% upside)

Analyst Consensus: Buy

Stock Forecasts